Champions Oncology, Inc. (CSBR) Income Statement
CSBR FY2026 at a glance
Fiscal year ended April 30, 2026 · U.S. dollarsCSBR revenue and net income
Where CSBR's revenue goes
FY2026Each bar shows an amount and its share of revenue. CSBR kept −2.0% of revenue as net income.
CSBR profit margins
CSBR growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +4.4% | +3.3% | +7.7% | +18.2% |
| Gross profit | −0.1% | +5.4% | +7.8% | +27.6% |
| Operating income | −123.5% | — | — | — |
| Net income | −125.0% | — | — | — |
| EPS (diluted) | −97.6% | — | −24.2% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CSBR quarterly EPS vs estimates
Champions Oncology beat the analyst EPS estimate in 5 of the last 8 quarters.
CSBR income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.4M | $56.9M | $50.2M | $53.9M | $49.1M | $41.0M | $32.1M | $27.1M | $20.2M | $15.4M |
| Cost of revenue | $30.9M | $28.4M | $29.4M | $29.5M | $23.6M | $21.4M | $17.0M | $14.3M | $10.6M | $9.7M |
| Gross profit | $28.5M | $28.6M | $20.8M | $24.3M | $25.5M | $19.6M | $15.1M | $12.8M | $9.7M | $5.7M |
| Research & development | $9.1M | $6.8M | $9.5M | $11.5M | $9.4M | $7.2M | $5.9M | $4.8M | $4.4M | $4.3M |
| Sales, general & admin | $20.5M | $16.9M | $18.1M | $17.2M | $15.5M | $12.0M | $10.9M | $7.7M | $6.6M | $8.2M |
| Total operating expenses | $29.7M | $23.7M | $27.7M | $28.8M | $24.9M | $19.2M | $17.0M | $12.5M | $11.0M | $12.5M |
| Operating income | −$1.1M | $4.8M | −$6.9M | −$4.4M | $607,000 | $366,000 | −$1.9M | $270,000 | −$1.4M | −$6.8M |
| Interest expense | — | $27,000 | $28,000 | — | $24,000 | $71,000 | $712,000 | $39,000 | $0 | $0 |
| Income before taxes | −$929,000 | $4.6M | −$7.3M | −$5.3M | $583,000 | $437,000 | −$2.0M | $231,000 | −$1.4M | −$6.9M |
| Income taxes | $246,000 | −$75,000 | −$32,000 | $68,000 | $35,000 | $75,000 | $130,000 | $103,000 | $33,000 | $19,000 |
| Net income | −$1.2M | $4.7M | −$7.3M | −$5.3M | $548,000 | $362,000 | −$2.1M | $128,000 | −$1.5M | −$6.9M |
| EBITDA | $448,000 | $6.3M | −$5.4M | −$3.0M | $2.2M | $1.6M | −$761,000 | $876,000 | −$994,000 | −$6.6M |
| EPS (diluted) | $0.01 | $0.42 | −$0.46 | −$0.35 | $0.08 | $0.04 | −$0.11 | $0.08 | −$0.12 | −$0.56 |
| Gross margin | 48.0% | 50.1% | 41.4% | 45.2% | 51.9% | 47.7% | 47.1% | 47.3% | 47.9% | 37.0% |
| Operating margin | −1.9% | 8.5% | −13.8% | −8.3% | 1.2% | 0.9% | −6.0% | 1.0% | −6.7% | −44.2% |
| Net margin | −2.0% | 8.3% | −14.5% | −9.9% | 1.1% | 0.9% | −6.5% | 0.5% | −7.3% | −44.7% |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.2M | $13.8M | $16.6M | $15.0M | $14.0M | $12.4M | $17.0M | $13.5M | $14.1M | $14.0M | $12.0M | $11.6M |
| Cost of revenue | $7.8M | $6.8M | $8.8M | $7.3M | $8.0M | $7.3M | $6.6M | $7.4M | $7.1M | $7.2M | $7.8M | $6.6M |
| Gross profit | $7.4M | $7.0M | $7.7M | $7.8M | $6.0M | $5.1M | $10.4M | $6.1M | $7.0M | $6.8M | $4.2M | $5.0M |
| Research & development | $2.3M | $2.1M | $2.3M | $2.6M | $2.1M | $2.0M | $1.7M | $1.7M | $1.5M | $2.0M | $2.2M | $2.5M |
| Sales, general & admin | $2.7M | $5.4M | $5.6M | $5.0M | $4.4M | $4.8M | $4.2M | $3.6M | $4.2M | $4.5M | $4.6M | $4.4M |
| Total operating expenses | $7.8M | $7.7M | $7.9M | $7.6M | $6.5M | $6.8M | $5.9M | $5.3M | $5.7M | $7.0M | $6.7M | $6.9M |
| Operating income | −$409,000 | −$631,000 | −$187,000 | $185,000 | −$507,000 | −$1.7M | $4.5M | $732,000 | $1.3M | −$271,000 | −$2.6M | −$2.0M |
| Income before taxes | −$415,000 | −$495,000 | −$237,000 | $255,000 | −$452,000 | −$2.0M | $4.5M | $739,000 | $1.3M | −$190,000 | −$2.5M | −$2.1M |
| Income taxes | $11,000 | $172,000 | $42,000 | $18,000 | $14,000 | −$129,000 | $23,000 | $11,000 | $21,000 | −$81,000 | $11,000 | $11,000 |
| Net income | −$426,000 | −$729,000 | −$279,000 | $299,000 | −$466,000 | −$1.8M | $4.5M | $728,000 | $1.3M | −$109,000 | −$2.5M | −$2.1M |
| EBITDA | −$95,000 | −$174,000 | $104,000 | $612,000 | −$94,000 | −$1.6M | $4.9M | $1.1M | $1.8M | $621,000 | −$2.0M | −$1.6M |
| EPS (diluted) | −$0.03 | −$0.05 | −$0.02 | $0.06 | $0.02 | −$0.07 | $0.33 | $0.05 | $0.11 | $0.01 | −$0.16 | −$0.15 |
| Gross margin | 48.5% | 50.8% | 46.7% | 51.7% | 42.9% | 41.1% | 61.2% | 44.9% | 49.7% | 48.2% | 34.7% | 42.8% |
| Operating margin | −2.7% | −4.6% | −1.1% | 1.2% | −3.6% | −13.9% | 26.4% | 5.4% | 9.5% | −1.9% | −21.4% | −16.9% |
| Net margin | −2.8% | −5.3% | −1.7% | 2.0% | −3.3% | −14.9% | 26.4% | 5.4% | 9.3% | −0.8% | −21.1% | −17.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CSBR's financial statements (latest annual report filed July 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CSBR financial results
In fiscal year 2026 (ended April 30, 2026), Champions Oncology reported revenue of $59.4 million, up 4.4% from the year before. It had a net loss of $1.2 million, a net profit margin of −2.0%. Diluted earnings per share came to $0.01. Over five years revenue grew at an average rate of 7.7% a year.
See the CSBR stock overview for the latest quote and news, or the CSBR chart for price history and technical indicators.
CSBR income statement FAQ
What is Champions Oncology's annual revenue?
Champions Oncology reported total revenue of $59.4 million for fiscal year 2026, which ended on April 30, 2026. That was up 4.4% from $56.9 million the previous year.
Is Champions Oncology profitable?
No. Champions Oncology reported a net loss of $1.2 million in fiscal 2026, a net profit margin of −2.0%; its operating margin was −1.9%.
What is Champions Oncology's gross margin?
Champions Oncology's gross margin was 48.0% in fiscal 2026: for every $100 of revenue, Champions Oncology kept $48 after the direct cost of its products and services.
How much does Champions Oncology spend on research and development?
Champions Oncology spent $9.1 million on research and development in fiscal 2026, 15.3% of revenue.
How fast is Champions Oncology growing?
Revenue grew 7.7% a year on average over the last five fiscal years, from $41.0 million to $59.4 million.
What are Champions Oncology's earnings per share?
Champions Oncology earned $0.01 per diluted share in fiscal 2026, compared with $0.42 a year earlier.
When does Champions Oncology's fiscal year end?
Champions Oncology's fiscal year ends in April. The latest annual report covers the year ended April 30, 2026 and was filed on July 27, 2026.